Humanigen Inc (fka HGENQ)

[cowtown jay]

Last week's presentation to the American Society of Hematology, detailing the patterns of Complete Remission Rates of CMML with Lenzilumab, did not result with the concurrent news of Australian approval, nor of any regulatory awards, such as expedited review or a Priority Review Voucher, that I was hoping to see. Today, there is very little dedicated focus on that topic on the Humanigen investors' X board.

The news was outstanding.

https://ash.confex.com/ash/2023/webprogram/Paper179706.html

The last thing I want to do is to be hopeful about a vaporous catalyst, some opportunity that just doesn't materialize. "I don't see how we could miss" that opportunity to treat CMML patients, even without additional Project Orbis data. To me, this remains one Humanigen's top contenders for regulatory approval.